SAN DIEGO, Calif.—October 24, 2011—The National Blood Foundation (NBF) today announced that David B. Perez, president and CEO of CaridianBCT and Terumo Transfusion, soon to become Terumo BCT, and chairman of the Terumo Blood Management Business Board, has been elected chairman of the National Blood Foundation's Board of Trustees. Selected from among the country's most accomplished leaders in blood services management, Mr. Perez will lead one of the nation's oldest and most prestigious academic research foundations in the transfusion medicine industry.
Effective immediately, Mr. Perez will commence a two-year term overseeing the NBF in fulfilling its mission to advance transfusion medicine and cellular and related biological therapies by funding scientific research that benefits patients and donors.
"The NBF is very fortunate to have a leader of David's experience, commitment and passion in this critical, guiding role," said Karen Shoos Lipton, JD, AABB CEO and ex-officio member of the NBF Board of Trustees. "I speak for everyone on the board in congratulating him on his new position and I look forward to working with him as we pursue our quest to support those individuals who are advancing research and education in the transfusion medicine and cellular therapy arena."
Mr. Perez takes over the position previously held by Mr. Dan Connor, MBA, president and CEO of Blood Systems and United Blood Services. Prior to today's election, Mr. Perez served as vice chair of the NBF Board of Trustees. He joined CaridianBCT in 1999, leading the strategic direction, growth and execution of the global business. A member of the NBF Council on Research and Development (CORD), he also serves in leadership positions for the Advanced Medical Technology Association, the Foundation for America's Blood Centers® and the Colorado BioScience Association.
"It is an honor to serve the NBF and its CORD members as chairman," said Mr. Perez. "For more than 28 years, NBF's main priority has always been to fund early career investigators in transfusion medicine and cellular therapies with grants totaling more than $500,000 annually. I am pleased to serve on the board in this capacity and to partner with other stakeholders in this field to meet this objective."
NBF has awarded more than $7 million in grants to 171 investigators since 1985.
Becoming Terumo BCT:
CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. The companies' products and services are designed to set new levels of performance today, and their innovation pipeline strives to substantially improve blood collection and processing, blood therapies and the development of cell therapies in the years ahead.
National Blood Foundation (NBF), established in 1983, has a history of supporting research and education that advances transfusion medicine and blood banking to benefit both patients and donors. Funds are raised annually from corporations, blood centers, foundations and individuals. NBF, a program of AABB, provides grants for scientific research in the fields of transfusion medicine, blood banking and cell ular therapies, and supports education initiatives that benefit the transfusion medicine community. Visit www.aabb.org/NBF.
Global Corporate Communications
Phone: +1 303.205.2546